Regulatory T cells (Treg) comprise multiple subsets and are important in controlling immunity and inflammation. However, the induction and mode of action of the various distinct Treg subsets remain ill defined, particularly in humans. Here, we describe a human CD8 ؉ lymphocyte activation gene-3 (LAG-3) ؉ CD25 ؉ FoxP3 ؉ Treg subset, which suppresses T cells partly through the secretion of CC chemokine ligand 4 (CCL4), which can inhibit T cell activation by interfering with T cell receptor signaling. CD8 ؉ Tregs are expanded by antigen in in vivo-primed donors, and can be detected in pathogeninfected human tissue. This CD8 ؉ LAG-3 ؉ CD25 ؉ FoxP3 ؉ CCL4 ؉ Treg subset thus may play a role in immunoregulation in humans, including infectious diseases.
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infectious diseases R egulatory T cells (Tregs) play an important role in maintaining immune responses within physiological boundaries, resolving inflammation and immune homeostasis. Dysfunctional Treg responses can lead to inflammatory and autoimmune diseases (1) , and depletion or neutralization of Tregs can enhance protective immunity against tumors (1) . Furthermore, Tregs have been implicated in infectious diseases, particularly in chronic or persistent infections (2, 3) , where they may prevent immunopathology, but also compromise pathogen eradication (2) . An imbalance between effector and Treg cells could precipitate reactivation of infection later in life; in Leishmania major, CD4 ϩ CD25 ϩ Tregs were found to promote parasite persistence (4) and disease reactivation (5) .
Whereas several Treg subsets have been identified in mice, limited information is available on human Treg, their subsets, and the mode of induction and their effector molecules. CD4 ϩ Tregs can be subdivided into naturally occurring and induced/adaptive Tregs. FoxP3 has been reported unique for Tregs in mice, but this is less clear in humans (6, 7) . Different subsets of adaptive Tregs exist: T R 1 secrete high levels of IL-10, whereas T H 3 secrete high levels of TGF-␤ (3). Recently, lymphocyte activation gene-3 (LAG-3) (CD223), an MHC class II binding CD4 homologue, was identified as a new Treg marker (8) . Also CD8 ϩ Tregs contribute to immunoregulation. It is thought that naive CD8 ϩ CD25
Ϫ cells can differentiate into CD8 ϩ Tregs in the presence of antigen (3) . Knowledge on CD8 ϩ Tregs in general, however, remains scarce compared with CD4 ϩ Tregs.
Mycobacterium tuberculosis (MTB) is one of the world's most successful pathogens. It has infected around one-third of the world's population, and causes chronic persistent infections even in the face of strong cellular and humoral immunity. Mycobacteria may be able to induce Tregs that dampen Th1 immunity and thus promote persistent infection. The only tuberculosis (TB) vaccine available, Mycobacterium bovis bacillus Calmette-Guérin (bacillus CalmetteGuérin), fails to protect efficiently against TB in adults (9). Bacillus Calmette-Guérin's inadequacy as TB vaccine may, similarly, at least in part (10), be accounted for by its ability to induce Tregs (11) . Tregs have been isolated from leprosy patients (12, 13) , which suppressed CD4 ϩ Th1 cells (12) (13) (14) . More recently, IL-10-producing T cells were reported in anergic TB patients (15) , and increased frequencies of CD4 ϩ CD25 HI T cells have been found in the circulation of TB patients (16, 17) . Thus, mycobacterial infections may provide a highly relevant model to dissect immuneregulatory pathways in humans.
In the present study, we describe a human Treg subset and a hitherto-unknown mechanism involved in immunoregulation.
Results
Antigen-Specific Induction of Treg Activity. To study antigen-specific induction of Treg cells, human peripheral blood mononuclear cells (PBMCs) were stimulated with various antigens for 6 days, expanded in IL-2, and titrated into stimulated autologous PBMCs. Significant inhibition of proliferation was observed on addition of live bacillus Calmette-Guérin-stimulated PBMCs. Both responses to antigen [purified protein derivative (PPD)] and mitogen [phytohemagglutinin (PHA)] were strongly suppressed. For comparison of different donors and experiments, results were expressed as stimulation indices in Fig. 1 b-d . IFN-␥ production in supernatants was similarly suppressed (data not shown).
Suppression was not influenced by IL-2 expansion of Tregs because suppression by antigen-stimulated PBMCs on day 6 (before IL-2 expansion) and on day 13 (after IL-2 expansion) gave similar results (data not shown). To eliminate the possibility that suppression was the result of cell crowding or medium nutrient depletion, similar numbers of antigen-unstimulated but IL-2-activated T cells were added. This did not result in decreased proliferation (Fig. 1b) . Also the addition of IL-2 (25 units/ml) did not abrogate suppression (data not shown).
Treg Induction Is Only Observed in Antigen Responder Donors. Live bacillus Calmette-Guérin-stimulated PBMCs from nonresponder donors consistently failed to induce T cells with suppressive capacity (Fig. 1d vs. Fig. 1 a and c) . This indicates that in vivo priming is necessary for induction of Treg activity. Also, tetanus toxoid (TT) stimulation induced similar suppression (Fig. 1e) . Furthermore, antigen-stimulated PBMCs also inhibited cognate peptide-induced proliferation of reporter Th1 clones in highly standardized assays (Fig. 1e) .
In addition to [ 3 H]thymidine ([ 3 H]TdR) incorporation, we also analyzed suppression by using cell cycle tracking dyes. Again, antigen-stimulated PBMCs strongly suppressed proliferation of PBMCs regardless of the stimuli used (Fig. 1f ) .
Taken together, these results show that, in antigen-primed individuals, recall antigens expand T cells with strong suppressive activity.
Restimulation Induces Human CD8 ؉ LAG-3 ؉ T Cells. To assess the cells responsible for suppression, we analyzed their surface markers. Stimulation with live bacillus Calmette-Guérin induced a 3-fold expansion of CD8 ϩ cells in responders but not in nonresponders (Fig. 2a) . A large subset of these CD3 ϩ CD8 ϩ T cells expressed LAG-3 and the majority also CD25 (Fig. 2b) . Nonresponders did not express LAG-3 or CD25 on CD8 ϩ T cells on antigen stimulation (Fig. 2b) . Mycobacterium leprae, Salmonella, and Staphyloccocus aureus enterotoxin B (SEB) also induced CD25 and LAG-3 on CD8 ϩ T cells of responders (Fig. 2c ). LAG-3 was present on a subset of cells in responders 6 days after stimulation (Fig. 2d) ; the percentage of positive cells and their LAG-3 staining intensity further increased over time.
CD8 ϩ CD25 ϩ cells also expressed other Treg markers, including cytotoxic T lymphocyte-associated antigen 4 (CD152), FoxP3, and partly also GITR, but not IFN-␥ (data not shown). A subset also expressed the Treg marker neuropilin-1 (18 Ϫ (data not shown). They also expressed the degranulation marker CD107a (LAMP1), granulysin, but not granzyme B.
Previously, we isolated CD4 ϩ Th and Treg T cell clones from a leprosy patient (12) . All five Treg clones constitutively expressed LAG-3, whereas both Th clones were LAG-3 negative (Fig. 2e) 
CD8
ϩ LAG-3 ϩ T cells to bacillus Calmette-Guérin or control antigen [supporting information (SI) Fig. 8 ]. Thus, in vivo antigen priming induces CD8
ϩ LAG-3 ϩ T cells, both in humans and in mice.
CD8 ؉ LAG-3 ؉ T Cells Inhibit Proliferation. Purified CD8 ϩ LAG-3 ϩ cells mediated potent suppression of both antigen-and mitogeninduced responses (Fig. 3a) . Because of the strong induction of this subset, it was not possible to purify sufficient CD8 ϩ LAG-3 Ϫ cells to perform similar suppression experiments; however, when sorting CD4 ϩ T cells into a LAG-3 ϩ and LAG-3 Ϫ population, only the former suppressed proliferation (unpublished work), supporting the notion that LAG-3-positive T cells are immunosuppressive.
To investigate whether CD8 ϩ LAG-3 ϩ Tregs were cytotoxic, as suggested by the expression of CD107a, perforin, and granulysin, Tregs were added to bacillus Calmette-Guérin-infected autologous macrophages. CD8
ϩ Tregs killed infected but not uninfected target cells (SI Fig. 9a ) while inhibiting T cell proliferation in an antigen-nonspecific manner (SI Fig. 9b ). The finding that cytotoxicity was antigen specific but suppression is not, suggested that killing was not the mechanism of suppression.
PBMC-Derived Supernatants Can Transfer Suppression. To investigate whether suppression depended on soluble factors, we designed a standardized assay to compare supernatants from different donors, a CD4
ϩ Th clone stimulated with its specific peptide. Day 6 supernatants from live bacillus Calmette-Guérin-stimulated PBMCs from responders but not from nonresponders suppressed proliferation (Fig. 3b) . The same supernatants also inhibited autologous PBMCs stimulated with mitogen or antigen (data not shown). No suppression was observed when supernatants from unstimulated cultures were transferred. Thus, suppression by Tregs could be transferred by a soluble factor.
Suppression Is Mediated Partly by CC Chemokine Ligand 4 (CCL4).
Live bacillus Calmette-Guérin stimulated cells from responders produced IFN␥, TNF␣, IL-13, IL-17 and GM-CSF (data not shown), whereas there was no detectable IL-10 or TGF-␤ (Ͻ10 pg/ml). Because supernatants could transfer suppression and IL-10 and TGF-␤ were not detectable, another soluble factor likely inhibited T cell proliferation. Whilst searching for suppressor molecules, we performed microarrays on in vitro anergized T cells which have strong suppressive activity (unpublished work; ref. 19 ). Tregs and anergized T cells represent different populations, but display a significant overlap (20) . We investigated genes that were strongly up-regulated in anergized T cells as potential suppressor molecules. In anergized T cells, mRNA expression of CCL3 (macrophage inflammatory protein-1␣) and CCL4 (macrophage inflammatory protein-1␤) was increased Ͼ100-fold and ranked among the top up-regulated genes. Also, LAG-3 mRNA was significantly increased in anergic T cells. No changes in mRNA levels of IL-10 and TGF-␤ were observed in anergized vs. control samples.
Although CCL3 and CCL4 are well known chemokines, a possible role in immune regulation has not been described. To investigate whether CCL3 and/or CCL4 were involved in suppression, stimulated PBMCs, and a T cell clone were analyzed in the presence of varying concentrations of CCL3 or CCL4. Only CCL4 was able to inhibit proliferation in a dose-dependent fashion (Fig. 4a) . In addition, anti-CCL4 but not anti-CCL3 or isotype control antibodies were capable of inhibiting suppression partly (39-59% reversal of suppression; in three independent experiments; P ϭ 0.008 Wilcoxon signed ranks test) (Fig. 4b) .
To demonstrate that Treg-derived CCL4 mediated suppression, we isolated highly purified (99%) CD8 ϩ LAG-3 ϩ cells (Fig.  5a ). These cells were stimulated with ␣CD3/28 in the absence of antigen-presenting cells, to rule out other sources of CCL4. The majority of cells produced CCL4 (94%), at the same time FoxP3 was expressed (Fig. 5a ). Supernatants contained high levels of CCL4 (Fig. 5b) ; transfer of these supernatants to a T cell clone caused a dose-dependent inhibition of proliferation, which was reversed by anti-CCL4, but not by the isotype control (Fig. 5c) .
Collectively, these results show that CD8 ϩ LAG-3 ϩ cells produce CCL4, which is able to suppress T cells, suggesting a immune-regulatory role of CCL4.
CD8 ؉ LAG-3 ؉ CCL4 ؉ Cells Are Present in Granulomas. To identify CD8 ϩ LAG-3 ϩ cells in vivo, we performed immunohistochemistry on Mycobacterium-infected human lymph nodes and tonsil sections. CD8 ϩ LAG-3 ϩ CCL4 ϩ cells (box) are present in Mycobacterium-infected lymph nodes (Fig. 6) ; triple-positive cells were predominantly found in granulomatous lesions in the vicinity of multinucleated giant cells, but not in paracortical areas. Quantification of cells in three different individuals showed a prevalence of Ϸ0.2% CD8 ϩ LAG-3 ϩ CCL4 ϩ T cells in normal tissue, whereas these cells were 20-fold enriched in granulomas (4% triple-positive cells). CD8 ϩ LAG-3 ϩ CCL4 ϩ cells were also found in human tonsil sections (data not shown). Furthermore, LAG-3 ϩ CCL4 ϩ , CD8 ϩ LAG-3 ϩ , and CD8 ϩ CCL4 ϩ cells were detectable as well. Thus, CD8 ϩ LAG-3 ϩ CCL4 ϩ triple-positive cells can be found in human pathogeninfected lesions.
CCL4 Inhibits Ca 2؉ Flux. Finally, to start dissecting potential mechanisms of regulation by CCL4, Ca 2ϩ flux in T cells was determined by flow cytometry. CCL4 was found to significantly reduce Ca 2ϩ flux early after activation (Fig. 7) . As expected, ionomycin-induced Ca 2ϩ fluxes were not affected (Right). Collectively, the results reveal a population of human Tregs characterized by expression of CD8 ϩ and LAG-3 ϩ , inducible only in in vivo-primed donors, and enriched in Mycobacteriuminfected granulomatous lesions. CCL4 is a suppressor factor secreted by CD8 ϩ LAG-3 ϩ Treg cells and inhibits T cell responses, at least in part through inhibition of Ca 2ϩ fluxing.
Discussion
In this study, we report a human Treg subset that expresses CD8 ϩ , LAG-3 ϩ , and can suppress T cell responses, at least in part, through the secretion of CCL4. CD8 ϩ Tregs were only found in primed but not in naive donors, suggesting that they are induced in vivo. CD8 ϩ LAG-3 ϩ CCL4 ϩ cells were strongly enriched in granulomas of human lymph nodes infected with mycobacteria. CCL4 was detected in supernatants of stimulated cultures, recombinant CCL4 inhibited proliferation, and anti-CCL4 antibodies partly reversed suppression. CCL4 reduced Ca 2ϩ flux on T cell antigen receptor triggering. Together, these results show that, in primed donors, recall antigens promote outgrowth of CD8 ϩ LAG-3 ϩ T cells, which suppress, at least in part via CCL4 as an identified Treg effector molecule in humans. Other, as yet unknown, soluble factors likely also contribute to the suppressive activity and need to be identified in future studies.
Studies on CD8 ϩ Tregs in humans are relatively scarce, and the majority of CD8 ϩ Tregs have been identified in animal models. CD8 ϩ Tregs in mice can be subdivided in at least two groups, namely Qa-1-restricted and non-Qa-1-restricted Tregs. Qa-1 is the mouse homologue of human HLA-E that can present self as well as microbial antigens (21) . In addition, non-Qa-1-restricted CD8 ϩ CD28 Ϫ Tregs that suppress via antigen-presenting cells have been described (21, 22) . To determine the effect of CCL4, CCL4 was added before ␣CD3 stimulation and Ca 2ϩ flux was measured. t ϭ 144, P ϭ 0.0047; t ϭ 177, P ϭ 0.008; t ϭ 210, P ϭ 0.29; paired t test.
In humans, autoreactive CD8 ϩ Tregs were characterized by constitutive expression of CD69, CD25, cytotoxic T lymphocyteassociated antigen 4, and FoxP3, and produced IL-4, IL-5, IL-13, and TGF-␤ but not IFN␥ (23) . Furthermore, suppressor CD8 ϩ T cell clones from immunologically unresponsive individuals with leprosy suppressed Th1 responses (14, 24) .
The CD8 ϩ Tregs identified in the present study share only some characteristics with previously described Tregs. They express CD25, cytotoxic T lymphocyte-associated antigen 4, and CD62L, but also CD28, and do not produce IFN-␥. The majority of CD8 ϩ LAG-3 ϩ cells is CD45RA Ϫ and CD27 Ϫ . Further analysis of cell surface markers will be essential to characterize and classify the various human CD8 ϩ Treg populations more precisely.
CCL4 (macrophage inflammatory protein-1␤) is a ␤ CC chemokine with 68% amino acid identity to CCL3 (macrophage inflammatory protein-1␣) (25) . Human CCL3 and CCL4 are inducible in most mature hematopoietic cells. CCL4 can be produced by T cells, including CD8 ϩ T cells (26) as well as by monocytes in response to mycobacteria (25) . MTB infection in mice induces increased expression of CCL3, CCL4, and CCL5 (RANTES) in the lung (27) . Interestingly, CCL4 has been identified as a TB susceptibility gene (28) .
Although CCL4 is commonly regarded as proinflammatory, several lines of evidence are compatible with an additional, regulatory role for CCL4. CCR5 is the only receptor for CCL4, CCR5-deficient mice (29) had no immunological abnormalities, but after Listeria monocytogenes infection displayed enhanced delayed-type hypersensitivity responses, decreased clearance of L. monocytogenes, and increased humoral immunity to T celldependent antigens (29) . CCR5 Ϫ/Ϫ mice infected with influenza similarly displayed hyperinflammatory responses (30) , and during dextran-induced colitis increased numbers of infiltrating CD4 ϩ T cells and Th2 cytokines were observed (31) . MTBinfected CCR5 Ϫ/Ϫ mice had increased T cell infiltrates in their lungs while controlling MTB infection (32) . Thus, the notion that CCR5 plays a yet poorly understood role in immune regulation may be explained, in part, by our present finding that CCL4 is an effector molecule secreted by Tregs.
In vitro expansion of CD8 ϩ Tregs is limited to primed donors, indicating that these cells are adaptive Tregs (33) . As for many Treg subsets, suppression by CD8 ϩ Tregs is not specific, and thus could cause linked suppression. Tregs could be both advantageous and detrimental during chronic infections. Tregs may prevent excessive inflammation and pathology but promote persistence of infection rather than eradication of the pathogen. The presence of CD8 ϩ LAG-3 ϩ CCL4 ϩ cells in granulomatous lesions of Mycobacterium-infected lymph nodes suggests that they can regulate, and perhaps promote, persisting infection in vivo. Imbalanced Treg responses may precipitate disease reactivation or dissemination, as shown in L. major infections (4, 5) . Nevetheless, persistent infection may provide a continuous source of antigen that maintains optimal memory T cell responses (4, 34) . Furthermore, inadvertent induction of Tregs by vaccines may limit induction of optimal protective responses. Bacillus Calmette-Guérin results in variable protection against TB in countries with a high prevalence of environmental mycobacteria, whereas it is rather effective in Western populations (35, 36) . Identification of the antigens and pathways involved in Treg induction will be an important avenue toward improving vaccine efficacy. Further analysis of Treg subsets will help to determine their in vivo prevalence and function in relation to disease and vaccine potency.
Experimental Procedures
Reagents. Reagents were as follows: PHA (Remel, Oxoid, Haarlem, The Netherlands), PPD (Statens Serum Institute, Copenhagen, Denmark), TT (The Netherlands Vaccine Institute, Bilthoven, The Netherlands), and SEB (Sigma-Aldrich, Zwijndrecht, The Netherlands).
Study Subjects. PBMCs were isolated by density centrifugation. Peripheral blood was obtained from healthy, in vitro PPD nonresponding (n ϭ 6) and responding donors (n ϭ 12). Some cells were stimulated with M. leprae or SEB. In addition, samples were obtained from TT (n ϭ 4) and Salmonella responders (n ϭ 2). All subjects volunteered to participate in this study, and informed consent was obtained.
Cell Cultures. PBMCs were cultured in Iscove's modified Dulbecco's medium (Invitrogen, Breda, The Netherlands) supplemented with 10% pooled human serum. Cells were restimulated with irradiated (30 Gy) PBMCs and ␣CD3/CD28 beads (Dynal Biotech, Hamburg, Germany) in the presence of IL-2 (25 units/ml; Cetus, Emeryville, CA).
Antigens used were as follows: (i) bacillus Calmette-Guérin-lux (Montreal), grown in 7H9 plus ADC until late-log phase, and aliquoted, frozen in 25% glycerol, and stored at Ϫ80°C; before use, bacteria were thawed and washed in PBS/0.05% Tween 80 (SigmaAldrich); infections were done at a multiplicity of infection (MOI) of 10; (ii) Salmonella typhimurium (WT SL1344) grown statically on LB agar for 18 h and added to PBMCs at a MOI of 10; after 45 min, extracellular bugs were killed with 30 g/ml gentamycin (SigmaAldrich) for 30 min; during the experiment, 5 g/ml gentamycin was present; (iii) M. leprae sonicate (Colorado State University, Fort Collins, CO) at a final concentration of 10 g/ml; (iv) TT at 1% of the stock (80 IE/ml); and (v) SEB at 2 g/ml.
Suppression Assays. PBMCs were stimulated for 6 days, and IL-2 (25 units/ml) was added. On day 13, cells were harvested and added in different ratios to autologous PBMCs stimulated with PPD (5 g/ml) or PHA (2 g/ml). On day 5, [
3 H]TdR (0.5 Ci/well) was added, and 18 h later incorporation was assessed. Values represent data from triplicate wells. Cells were analyzed by FACS on days 6 and 13, and supernatants were harvested for cytokine measurements.
Alternatively, cell tracking dyes were used and cells were mea- FACS Analysis. Cells were stained with anti-LAG-3 (Immutep SA) combined with goat-anti-mouse-phycoerythrin (PE) (DakoCytomation, Heverlee, Belgium). Other antibodies used were as follows: CD4-PerCP, CD8-allophycocyanin (APC)/PerCP, CD25-FITC, CD45RA-CyChrome, CD27-PE, CD28-PE, CD57-FITC, CD62L-FITC, cytotoxic T lymphocyte-associated antigen-4-PE, CD107-PE, CD127-PE, HLA-DR-FITC (all BD Biosciences); GITR-PE (R&D Systems, Abingdon, U.K.).
Intracellular staining, after adding brefeldin A for the last 18 h (3 g/ml; Sigma-Aldrich), was done by using Intrastain reagents (DakoCytomation) and the following antibodies: IFN-␥-APC (BD Pharmingen, San Diego, CA), Perforin-PE (BD Biosciences); Granzyme B-PE/APC (CLB, Amsterdam, The Netherlands/Caltag Laboratories, Burlingame, CA); FoxP3-FITC (eBioscience, San Diego, CA); polyclonal rabbit serum against human granulysin (Dr. Krensky, Stanford, CA); and FITCconjugated goat anti-rabbit (BD Biosciences). Samples were measured on a FACSCalibur or LSRII and analyzed by using CellQuestPro and FACSDiva software (BD Biosciences).
Mouse Experiments. Female BALB/c mice (18-20 weeks; Charles River, Maastricht, The Netherlands) were immunized s.c. with
